Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Allergan Inc. (AGN) Push For Actavis plc (ACT) Merger Shunning Valeant Pharmaceuticals Intl Inc. (VRX) Hostile Bid

Bill Ackman may be failing all together on his push to get Allergan to agree to a merger agreement with Valeant Pharmaceuticals Intl Inc. (NYSE:VRX). Bloomberg’s Olivia Sterns reports that Allergan, Inc. (NYSE:AGN)  is giving Valeant pharmaceutical’s $54 billion takeover push a cold shoulder and remains focused  on talks with rival Actavis plc (NYSE:ACT).

Valeant Pharmaceuticals Intl Inc (NYSE:VRX)

“Its big news and it’s a big thumb in the eye for Bill Ackman. [..] The news is that Allergan is said to be in Active talks, these talks are private with Actavis this would be a potential alternative deal, “said Mrs. Sterns.

In a regulatory filing to the SEC, Allergan, Inc. (NYSE:AGN) said that discussions about a potential merger transaction were underway and could lead to negotiations. Allergan has vehemently opposed Valeant Pharmaceuticals $54 billion hostile takeover arguing that its growth will be diminished with the merger as Valeant seeks to cut costs deeply.

Allergan also argues that Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) is bloated and will only benefit from the merger as one of the ways of paying up debt accumulated from other acquisitions carried in the past. Allergan had reportedly gone to court to seek an injunction that would have barred Mr. Ackman from voting at the shareholder meeting.

“Bill Ackerman has been pushing for Valeant to take over Allergan; he is on the board of Allergan, Inc. (NYSE:AGN). He has been trying to get rid of the directors who opposed the deal with Valeant.  Instead, we know that Valeant has offered about $54 billion, Allergan thinks that is grossly inadequate,” said Mrs. Sterns.

Allergan stock continues to be the biggest beneficiary of the ongoing standoff with Valeant as the stock has risen to record highs of $197 way above Valeant’s valuation of $54 billion. Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) has already stated that it would be willing to raise its bid to at least $200 a share.

Allergan, Inc. (NYSE:AGN) is reportedly taking issue with Valeant Pharmaceutical’s mode of operations especially after carrying out acquisitions. Valeant Pharmaceuticals has built its business in the past through acquisitions as well as resorting to cut back on research and development expenses. Allergan, Inc. (NYSE:AGN) is reportedly afraid that the same will occur if it is to agree to a merger.

Warren Buffett and BillionairesFree Report: Warren Buffett and 12 Billionaires Are Crazy About These 7 Stocks

Let Warren Buffett, David Einhorn, George Soros, and David Tepper WORK FOR YOU. If you want to beat the low cost index funds by an average of 6 percentage points per year look no further than Warren Buffett’s stock picks. That’s the margin Buffett’s stock picks outperformed the market since 2008. In this free report, Insider Monkey’s market beating research team identified 7 stocks Warren Buffett and 12 other billionaires are crazy about. CLICK HERE NOW

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.